m6A RNA methylation in sepsis-induced cardiomyopathy: direct cardiac mechanisms, emerging therapeutic targets, and translational gaps - Takeaways - MDSpire

m6A RNA methylation in sepsis-induced cardiomyopathy: direct cardiac mechanisms, emerging therapeutic targets, and translational gaps

  • By

  • Fengmei Zhang

  • Lijun Zhang

  • Yuhan Wang

  • May 4, 2026

  • 0 min

Share

  • 1

    Sepsis-induced cardiomyopathy (SICM) affects 40-60% of sepsis patients and significantly increases mortality rates.

  • 2

    N6-methyladenosine (m6A) RNA modification plays a crucial role in regulating cardiac responses to sepsis.

  • 3

    The eraser FTO consistently shows cardioprotective effects, while ALKBH5 exacerbates pyroptotic injury in cardiac cells.

  • 4

    m6A pathways converge on the SLC7A11/GPX4/NRF2 antioxidant network, highlighting potential therapeutic targets.

  • 5

    Significant translational gaps exist, including reliance on lipopolysaccharide models and lack of human validation for m6A-targeted therapies.

Original Source(s)

m6A RNA methylation in sepsis-induced cardiomyopathy: direct cardiac mechanisms, emerging therapeutic targets, and translational gaps

  • by Fengmei Zhang, Lijun Zhang, Yuhan Wang

  • May 4, 2026

Related Content

Aspirin is associated with improved outcomes in sepsis patients with atrial fibrillation: an analysis of the MIMIC-IV and eICU-CRD databases

Quantitative CT assessment of intrathoracic visceral fat depots and their association with incident heart failure in asymptomatic adults

Biomolecular mechanisms of cardiac amyloidosis and its cardiovascular pathological basis